Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics recently posted robust interim data for its Phase 1/2 trials studying CTX-001 gene-editing therapy for the blood disorders dubbed beta-thalassemia and sickle cell disease.

CRISPR: On The Cusp Of Aggressive Growth

Here's why 2020's going to be a big year for three gene-editing stocks.

More CRISPR Stock Catalysts Ahead

The gene-editing pioneer announced the pricing of a public stock offering.

Here's Why CRISPR Therapeutics Stock Is Falling Today

ZUG, Switzerland and CAMBRIDGE, Mass., Nov.  20, 2019  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 4,250,000 common shares at a public offering price of $64.50 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 637,500 common shares at the public offering price less the underwriting discount. CRISPR Therapeutics anticipates its gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $274.1 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about November 25, 2019, subject to customary closing conditions.

CRISPR Therapeutics Announces  Pricing of Public Offering of Common Shares

Vertex Pharmaceuticals

Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.

Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data

ZUG, Switzerland and CAMBRIDGE, Mass., Nov.  19, 2019  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of 4,250,000 common shares. In addition, the underwriters will have a 30-day option to purchase up to 637,500 additional common shares at the public offering price less the underwriting discount.

CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

The industry's most advanced drug candidate based on CRISPR gene editing has data from the first two patients.

Here's Why CRISPR Stocks Are Soaring Today

Crispr Therapeutics AG (NASDAQ: CRSP) shares are ripping higher after the company focused on developing gene therapies using its proprietary CRISPR/Cas9 platform said CTX001, a gene-editing therapy it's co-developing with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), produced positive results in human trials.

Crispr's Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study

Shares of Crispr Therapeutics jumped Tuesday after the biotech company's gene-editing approach to sickle cell disease and beta thalassemia, both blood diseases, showed early promise.

This Biotech Stock Rockets After Its Gene Drug Shows Promise

CRISPR is a great addition to your stock wish list. If we get a correction, this is a solid long-term addition to your portfolio.

CRISPR Has the Potential to Cure Cancer and Make You Triple-Digit Gains

Intellia Therapeutics

Which stock wins in a matchup between these two gene-editing pioneers?

Better Buy: CRISPR Therapeutics vs. Intellia Therapeutics

The gene-editing pioneer provided investors with an encouraging quarterly update.

Here's Why Crispr Therapeutics Gained 22.8% in October

Beyond Meat

Etsy

Lumentum Holdings

NVIDIA

Pinterest

Shopify

Snap

Skyworks Solutions

Tiffany & Co.

Twilio

Twitter

Xilinx

Current ratio is a popular way for investors to assess the health of a stock’s balance sheet.

15 Stocks With A High Current Ratio

Editas Medicine

Guardant Health Inc

Illumina

Invitae

REGENXBIO

Veracyte

As investors shift out of growth names and to more defensive pockets of the market, market watchers now see these biotech players as undervalued.

8 Undervalued Biotech Stocks to Watch Now

Recent updates from the gene-editing pioneer give investors lots to look forward to.

3 Reasons CRISPR Therapeutics Stock Can Reach Record Highs Again

Crispr Therapeutics AG (NASDAQ: CRSP) shares were solidly higher Monday after the company reported third-quarter results and provided a business update.

BTIG: Crispr Could Be A Takeover Target For Vertex

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 352.63% and 3252.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Q3 Earnings and Revenues Surpass Estimates

-Provides update from ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies-

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results

The media has gotten a little carried away (again) by overlooking a simple technical flaw in the latest gene editing tool.

There's Yet Another Gene Editing Technique, but It Has 1 Glaring Problem

Despite an impressive platform and pipeline, I have avoided establishing a long-term investment in CRISPR Therapeutics due to a premium valuation and unjustified selloffs.

CRISPR Therapeutics: At The Top Of My Shopping List

CRISPR Therapeutics (CRSP) looks to strengthen its CAR-T therapy programs through its agreement with KSQ Therapeutics.

CRISPR Therapeutics Enters New License Agreement, Shares Up

- CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs -

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

Despite working together on a major project, these two biotech stocks couldn't be more different from a growth perspective.

Forget Vertex Pharmaceuticals; CRISPR Therapeutics Is a Better Biotech Growth Stock

﻿-New data demonstrate successful differentiation of CRISPR-edited human pluripotent stem cells to pancreatic precursor cells-

CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019

Regeneron Pharmaceuticals

The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.

News for CRISPR Therapeutics Stock (CRSP)